Pest control standards in pharmaceutical manufacturing

Quick overview

• Pests can contaminate drug products and trigger FDA enforcement actions.
• FDA CGMP regulations require strict pest control in all pharmaceutical manufacturing facilities.
• The core regulatory framework is found in Title 21 of the Code of Federal Regulations.
• An integrated pest management (IPM) approach is the most effective way to stay compliant.

Pharmaceutical manufacturing is one of the most tightly regulated industries in the United States. Every step of the production process, from raw material handling to final packaging, is subject to oversight designed to protect product quality and patient safety. Pest control is no exception. In fact, it's one of the areas where the FDA has issued some of its most serious enforcement actions.

What the FDA says about pest control in pharma manufacturing

The core regulatory framework for pharmaceutical manufacturing in the US is found in Title 21 of the Code of Federal Regulations, specifically Parts 210 and 211. These are the Current Good Manufacturing Practice (CGMP) regulations enforced by the FDA and set the minimum standards for how drug products must be manufactured, processed, packed, and held.

Section 21 CFR 211.56 is the most directly relevant to pest management. It requires that any building used in the manufacture, processing, packing, or holding of drug products must be:

• Maintained in a clean and sanitary condition
• Free of infestation by rodents, birds, insects, and other vermin
• Supported by written procedures that assign responsibility for sanitation and describe cleaning schedules, methods, and materials in sufficient detail

The regulation also requires written procedures for the use of rodenticides, insecticides, fungicides, and fumigating agents. These procedures must be designed to prevent contamination of equipment, components, drug product containers, and finished products. Any pest control materials used must be registered and applied in accordance with the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).

Critically, these sanitation requirements apply to everyone working in the facility, including contractors and temporary employees, not just full-time staff.

Why pests are such a serious risk in pharmaceutical settings

In most industries, a pest sighting is a nuisance. In pharmaceutical manufacturing, it can be a regulatory crisis.

Drug products, particularly sterile injectables and topical formulations, are highly vulnerable to biological contamination. Rodents, cockroaches, flies, and other insects can introduce pathogens like Salmonella, Listeria, and E. coli into production environments. Even a single pest event near a filling line or packaging area can compromise an entire batch.

The FDA takes this seriously. The agency has issued numerous warning letters to pharmaceutical manufacturers specifically citing pest-related CGMP violations, including live insects found in aseptic production rooms, rodent droppings near drug product bags, and gaps in facility walls that allowed pests to enter clean areas. In several cases, these findings led to product recalls and import alerts.

The FDA's own data shows that FY 2025 saw the highest number of CGMP warning letters in over 20 years, with facility design and sanitation deficiencies among the most frequently cited violations.

Key pest control requirements under CGMP

CGMP regulations cover specific, practical requirements that touch on everything from building design to pest sighting documentation. Knowledge of the requirements is the first step toward building a program that holds up under FDA scrutiny.

Facility design and construction

The physical design of a pharmaceutical facility plays a major role in pest prevention. Under 21 CFR 211.42, facilities must be designed and constructed to prevent pest entry and harborage. This means:

• Smooth, sealed interior surfaces on walls, floors, and ceilings that can be effectively cleaned and disinfected
• No gaps around pipes, ducts, or utility penetrations that could serve as entry points
• Proper drainage designed to prevent backflow and standing water
  Adequate ventilation to control temperature and humidity, which can otherwise attract pests
• Separate storage areas for raw materials, packaging, and finished products, maintained under appropriate conditions

Exterior grounds also matter. Overgrown vegetation, standing water, and improperly managed waste areas can all create harborage conditions that draw pests toward the building. Vegetation management around the facility perimeter is an often-overlooked but important part of a compliant pest program

Written procedures and documentation

One of the most common reasons pharmaceutical companies receive FDA citations is not the presence of pests, but the absence of adequate written procedures. The regulations require documented programs that cover:

• Cleaning schedules and methods for all areas of the facility
• Pest monitoring protocols, including the type, placement, and inspection frequency of monitoring devices
• Procedures for pest control materials, including approved products, application methods, and safeguards against product contamination
• Records of all pest activity and corrective actions taken

These records are not just good practice. They are what an FDA investigator will ask to see during an inspection. A sanitation audit from a qualified provider can help identify gaps in your documentation before an inspector does.

Pest control materials and contamination prevention

Under CGMP, pest control materials, including rodenticides, insecticides, and fumigation agents, must not contaminate equipment, starting materials, packaging, or finished drug products. This creates a real tension: you need to control pests, but the methods you use must not introduce new contamination risks.

This is one reason why pharmaceutical pest control requires a more specialized approach than standard commercial pest management. Treatment selection, placement, and timing all need to be carefully managed in relation to production schedules and product exposure risks.

Common pest threats in pharmaceutical manufacturing

Pharmaceutical facilities can attract a range of pests, and the consequences of an infestation go well beyond a typical nuisance. In a regulated manufacturing environment, even low-level pest activity can put product integrity and CGMP compliance at risk. 

• Rodents - Rats and mice are among the most serious pest threats in any manufacturing environment. They can contaminate products and surfaces with droppings, urine, and hair. They can also chew through packaging, wiring, and structural materials. In pharmaceutical settings, even indirect contact between rodents and product areas can trigger a CGMP violation. 
• Cockroaches  - Cockroaches thrive in warm, humid environments and are capable of spreading a range of pathogens. They are particularly difficult to detect early because they are nocturnal and tend to hide in wall voids, under equipment, and in drains. Cockroach control in pharmaceutical facilities requires a combination of monitoring, targeted baiting, and sanitation improvements. 
• Flies  - Flies are a significant contamination risk in any facility where products are exposed during manufacturing or packaging. They can carry pathogens on their bodies and deposit them on surfaces and products. Fly control in pharmaceutical environments typically relies on insect light traps, air curtains, and strict waste management protocols, rather than chemical sprays that could compromise product integrity. 

The role of integrated pest management in pharma compliance

Integrated pest management (IPM) is the approach most aligned with pharmaceutical regulatory expectations. Rather than relying on reactive chemical treatments, IPM focuses on prevention, monitoring, and targeted intervention. A well-designed IPM program for a pharmaceutical facility typically includes:

• Regular facility inspections to identify structural vulnerabilities and early signs of pest activity
• Monitoring devices such as rodent bait stations, insect light traps, and sticky monitors placed at strategic points throughout the facility
• Exclusion measures to seal entry points and eliminate harborage areas
• Sanitation reviews to address conditions that attract or sustain pests
• Targeted treatments applied only when monitoring data indicates a need, using products and methods appropriate for the environment
• Detailed service reports that support audit documentation requirements

This approach reduces reliance on chemical treatments, which is important in environments where contamination risk is high. It also generates the kind of documented evidence trail that regulators expect to see.

For facilities managing rodent control in particular, IPM-based programs that combine exclusion, monitoring, and targeted baiting tend to be far more effective than reactive treatments alone.

Work with a pest management partner who understands pharma compliance

Pharmaceutical facilities operate under some of the most demanding regulatory standards in any industry. Pest control is not a peripheral concern; it is a core component of CGMP compliance and product quality.

At Presto-X, our commercial pest control team works with pharmaceutical manufacturers to build programs that are designed around your facility's specific risks, production schedules, and audit requirements. 

From 24/7 digital pest management and monitoring to targeted treatments and sanitation audits, we can help you stay ahead of pest issues before they become compliance problems.

Get in touch to schedule a free inspection and find out how we can support your facility's pest management program.